Ensign Peak Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
|
|||||
|
2023
Q2 | $12.9M | Buy |
|
|||||
|
2023
Q1 | $10.8M | Buy |
|
|||||
|
2022
Q4 | $2.69M | Sell |
|
|||||
|
2022
Q3 | $1.96M | Buy |
|
|||||
|
2022
Q2 | $1.91M | Buy |
|
|||||
|
2022
Q1 | $702K | Buy |
|
|||||
|
2021
Q4 | $174K | Buy |
|
|||||
|
2021
Q3 | – | Sell |
|
|||||
|
2021
Q2 | $1.59M | Buy |
|
|||||
|
2021
Q1 | $226K | Hold |
|
|||||
|
2020
Q4 | $281K | Sell |
|
|||||
|
2020
Q3 | $939K | Buy |
|
|||||
|
2020
Q2 | $450K | Buy |
|
|||||
|
2020
Q1 | $335K | Sell |
|
|||||
|
2019
Q4 | $617K | Buy |
|